TY - JOUR
T1 - The role of cytokines in the initiation and progression of myelofibrosis
AU - Hasselbalch, Hans C.
PY - 2013/4/1
Y1 - 2013/4/1
N2 - Myelofibrosis (MF) is a life-threatening blood cancer characterized by progressive bone marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms. Abnormal expression and activity of a number of proinflammatory cytokines are associated with MF, in which immune dysregulation is pronounced as evidenced by dysregulation of several immune and inflammation genes. The discovery of the Janus kinase 2 (JAK2) V617F mutation has led to the development of a number of JAK1/2 inhibitors in the treatment of MF and similar neoplasms. Here, the role of cytokines in MF initiation and progression is discussed, the impact of current therapies is reviewed, and new combination therapies are proposed, such as JAK1/2 inhibitors with interferons, statins, and epigenetic modifiers for patients with MF and related neoplasms.
AB - Myelofibrosis (MF) is a life-threatening blood cancer characterized by progressive bone marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms. Abnormal expression and activity of a number of proinflammatory cytokines are associated with MF, in which immune dysregulation is pronounced as evidenced by dysregulation of several immune and inflammation genes. The discovery of the Janus kinase 2 (JAK2) V617F mutation has led to the development of a number of JAK1/2 inhibitors in the treatment of MF and similar neoplasms. Here, the role of cytokines in MF initiation and progression is discussed, the impact of current therapies is reviewed, and new combination therapies are proposed, such as JAK1/2 inhibitors with interferons, statins, and epigenetic modifiers for patients with MF and related neoplasms.
KW - Chronic inflammation
KW - Cytokines
KW - Interferon-alpha2
KW - JAK-inhibitor
KW - Myelofibrosis
KW - Myeloproliferative neoplasms
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=84875279909&partnerID=8YFLogxK
U2 - 10.1016/j.cytogfr.2013.01.004
DO - 10.1016/j.cytogfr.2013.01.004
M3 - Review
C2 - 23415024
AN - SCOPUS:84875279909
VL - 24
SP - 133
EP - 145
JO - Cytokine and Growth Factor Reviews
JF - Cytokine and Growth Factor Reviews
SN - 1359-6101
IS - 2
ER -